Drugs Made In America Acquisition (DMAA) Competitors

$10.58 +0.01 (+0.09%)

Closing price 03:52 PM Eastern

Extended Trading

$10.57 -0.01 (-0.09%)

As of 04:10 PM Eastern

DMAA vs. ORC, LADR, TIGR, SAFE, and CSR

Should you be buying Drugs Made In America Acquisition stock or one of its competitors? The main competitors of Drugs Made In America Acquisition include Orchid Island Capital (ORC), Ladder Capital (LADR), UP Fintech (TIGR), Safehold (SAFE), and Centerspace (CSR). These companies are all part of the "trading" industry.

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Orchid Island Capital (NYSE:ORC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

: In the previous week, Orchid Island Capital had 7 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 7 mentions for Orchid Island Capital and 0 mentions for Drugs Made In America Acquisition. Orchid Island Capital's average media sentiment score of 0.76 beat Drugs Made In America Acquisition's score of 0.00 indicating that Orchid Island Capital is being referred to more favorably in the media.
Company Overall Sentiment
Orchid Island Capital Positive
Drugs Made In America Acquisition Neutral
: Orchid Island Capital currently has a consensus target price of $7.50, suggesting a potential upside of 8.15%. Given Orchid Island Capital's stronger consensus rating and higher probable upside, equities research analysts plainly believe Orchid Island Capital is more favorable than Drugs Made In America Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchid Island Capital
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
Drugs Made In America Acquisition
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Orchid Island Capital has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.
: 32.7% of Orchid Island Capital shares are held by institutional investors. 0.4% of Orchid Island Capital shares are held by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Orchid Island Capital's return on equity of 10.24% beat Drugs Made In America Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Orchid Island Capital N/A 10.24% 1.19%
Drugs Made In America Acquisition N/A N/A N/A
: Orchid Island Capital has higher revenue and earnings than Drugs Made In America Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orchid Island Capital $414M 3.36 $159.03M $0.75 9.25
Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Company	Overall Sentiment
Orchid Island Capital	Positive
Drugs Made In America Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchid Island Capital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Orchid Island Capital	N/A	10.24%	1.19%
Drugs Made In America Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchid Island Capital	$414M	3.36	$159.03M	$0.75	9.25
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Orchid Island Capital beats Drugs Made In America Acquisition on 9 of the 10 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Ladder Capital?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Ladder Capital (NYSE:LADR) are both small-cap trading companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

: Ladder Capital has higher revenue and earnings than Drugs Made In America Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Drugs Made In America Acquisition N/A N/A N/A N/A N/A
Ladder Capital $390.29M 3.35 $64.18M $0.44 23.35
: In the previous week, Ladder Capital had 5 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 5 mentions for Ladder Capital and 0 mentions for Drugs Made In America Acquisition. Ladder Capital's average media sentiment score of 1.16 beat Drugs Made In America Acquisition's score of 0.00 indicating that Ladder Capital is being referred to more favorably in the news media.
Company Overall Sentiment
Drugs Made In America Acquisition Neutral
Ladder Capital Positive
: Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Ladder Capital has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
: Ladder Capital has a consensus target price of $12.75, indicating a potential upside of 24.12%. Given Ladder Capital's stronger consensus rating and higher possible upside, analysts plainly believe Ladder Capital is more favorable than Drugs Made In America Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Ladder Capital
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Ladder Capital has a net margin of 13.82% compared to Drugs Made In America Acquisition's net margin of 0.00%. Ladder Capital's return on equity of 5.73% beat Drugs Made In America Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Drugs Made In America Acquisition N/A N/A N/A
Ladder Capital 13.82% 5.73% 1.70%
: 62.3% of Ladder Capital shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Comparatively, 12.0% of Ladder Capital shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Ladder Capital	$390.29M	3.35	$64.18M	$0.44	23.35

Company	Overall Sentiment
Drugs Made In America Acquisition	Neutral
Ladder Capital	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ladder Capital	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Ladder Capital	13.82%	5.73%	1.70%

Summary

Ladder Capital beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to UP Fintech?

Drugs Made In America Acquisition (NASDAQ:DMAA) and UP Fintech (NASDAQ:TIGR) are both small-cap trading companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

: UP Fintech has a net margin of 28.82% compared to Drugs Made In America Acquisition's net margin of 0.00%. UP Fintech's return on equity of 21.87% beat Drugs Made In America Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Drugs Made In America Acquisition N/A N/A N/A
UP Fintech 28.82% 21.87% 2.05%
: UP Fintech has a consensus target price of $11.83, indicating a potential upside of 77.67%. Given UP Fintech's stronger consensus rating and higher possible upside, analysts plainly believe UP Fintech is more favorable than Drugs Made In America Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
UP Fintech
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: UP Fintech has higher revenue and earnings than Drugs Made In America Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Drugs Made In America Acquisition N/A N/A N/A N/A N/A
UP Fintech $538.71M 2.31 $170.90M $0.91 7.32
: 9.0% of UP Fintech shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, UP Fintech has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
: In the previous week, UP Fintech had 1 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 1 mentions for UP Fintech and 0 mentions for Drugs Made In America Acquisition. UP Fintech's average media sentiment score of 1.20 beat Drugs Made In America Acquisition's score of 0.00 indicating that UP Fintech is being referred to more favorably in the news media.
Company Overall Sentiment
Drugs Made In America Acquisition Neutral
UP Fintech Positive

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
UP Fintech	28.82%	21.87%	2.05%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
UP Fintech	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
UP Fintech	$538.71M	2.31	$170.90M	$0.91	7.32

Company	Overall Sentiment
Drugs Made In America Acquisition	Neutral
UP Fintech	Positive

Summary

UP Fintech beats Drugs Made In America Acquisition on 11 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Safehold?

Safehold (NYSE:SAFE) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

: Safehold has a net margin of 28.58% compared to Drugs Made In America Acquisition's net margin of 0.00%. Safehold's return on equity of 4.78% beat Drugs Made In America Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Safehold 28.58% 4.78% 1.61%
Drugs Made In America Acquisition N/A N/A N/A
: Safehold has higher revenue and earnings than Drugs Made In America Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Safehold $385.55M 2.73 $114.47M $1.59 9.22
Drugs Made In America Acquisition N/A N/A N/A N/A N/A
: Safehold has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
: Safehold currently has a consensus target price of $19.00, indicating a potential upside of 29.68%. Given Safehold's stronger consensus rating and higher probable upside, analysts clearly believe Safehold is more favorable than Drugs Made In America Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Safehold
1 Sell rating(s)
7 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.18
Drugs Made In America Acquisition
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Safehold had 12 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 12 mentions for Safehold and 0 mentions for Drugs Made In America Acquisition. Safehold's average media sentiment score of 0.08 beat Drugs Made In America Acquisition's score of 0.00 indicating that Safehold is being referred to more favorably in the media.
Company Overall Sentiment
Safehold Neutral
Drugs Made In America Acquisition Neutral
: 70.4% of Safehold shares are owned by institutional investors. 3.8% of Safehold shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Safehold	28.58%	4.78%	1.61%
Drugs Made In America Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Safehold	$385.55M	2.73	$114.47M	$1.59	9.22
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Safehold	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Safehold	Neutral
Drugs Made In America Acquisition	Neutral

Summary

Safehold beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Centerspace?

Centerspace (NYSE:CSR) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

: Centerspace has a net margin of 2.93% compared to Drugs Made In America Acquisition's net margin of 0.00%. Centerspace's return on equity of 0.93% beat Drugs Made In America Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Centerspace 2.93% 0.93% 0.39%
Drugs Made In America Acquisition N/A N/A N/A
: Centerspace has higher revenue and earnings than Drugs Made In America Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Centerspace $273.66M 4.03 $17.59M $0.45 146.05
Drugs Made In America Acquisition N/A N/A N/A N/A N/A
: Centerspace has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.
: Centerspace currently has a consensus target price of $68.83, indicating a potential upside of 4.73%. Given Centerspace's stronger consensus rating and higher probable upside, equities analysts clearly believe Centerspace is more favorable than Drugs Made In America Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Centerspace
0 Sell rating(s)
5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.29
Drugs Made In America Acquisition
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Centerspace had 11 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 11 mentions for Centerspace and 0 mentions for Drugs Made In America Acquisition. Centerspace's average media sentiment score of 0.02 beat Drugs Made In America Acquisition's score of 0.00 indicating that Centerspace is being referred to more favorably in the media.
Company Overall Sentiment
Centerspace Neutral
Drugs Made In America Acquisition Neutral
: 79.0% of Centerspace shares are held by institutional investors. 0.5% of Centerspace shares are held by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Centerspace	2.93%	0.93%	0.39%
Drugs Made In America Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centerspace	$273.66M	4.03	$17.59M	$0.45	146.05
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centerspace	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Centerspace	Neutral
Drugs Made In America Acquisition	Neutral

Summary

Centerspace beats Drugs Made In America Acquisition on 11 of the 12 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAA vs. The Competition

Export

Metric	Drugs Made In America Acquisition	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$356.39M	$329.65M	$5.63B	$11.77B
Dividend Yield	N/A	N/A	5.26%	5.26%
P/E Ratio	N/A	0.47	15.31	23.23
Price / Sales	N/A	732.60	977.50	75.49
Price / Cash	N/A	132.82	91.49	53.90
Price / Book	N/A	259.33	4.42	6.69
Net Income	N/A	-$64.15M	$1.15B	$332.64M
7 Day Performance	0.19%	1.39%	1.01%	2.01%
1 Month Performance	0.67%	2.52%	4.06%	9.19%
1 Year Performance	N/A	6.97%	21.63%	39.59%

Drugs Made In America Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAA Drugs Made In America Acquisition	N/A	$10.58 +0.1%	N/A	N/A	$356.39M	N/A	N/A	2
ORC Orchid Island Capital	2.3603 of 5 stars	$7.09 +0.8%	$7.50 +5.9%	N/A	$1.41B	$145.60M	9.45	2,018	Analyst Downgrade
LADR Ladder Capital	4.9747 of 5 stars	$10.33 +0.4%	$12.75 +23.5%	N/A	$1.31B	$213.42M	23.47	60	Positive News Analyst Upgrade
TIGR UP Fintech	3.2784 of 5 stars	$6.78 +2.8%	$11.83 +74.4%	N/A	$1.27B	$612.06M	7.46	1,193	Positive News
SAFE Safehold	4.6311 of 5 stars	$14.89 -7.1%	$19.00 +27.6%	N/A	$1.15B	$385.55M	9.31	120	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. ORC, LADR, TIGR, SAFE, and CSR

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Summary

How does Drugs Made In America Acquisition compare to Ladder Capital?

Summary

How does Drugs Made In America Acquisition compare to UP Fintech?

Summary

How does Drugs Made In America Acquisition compare to Safehold?

Summary

How does Drugs Made In America Acquisition compare to Centerspace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. ORC, LADR, TIGR, SAFE, and CSR

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Summary

How does Drugs Made In America Acquisition compare to Ladder Capital?

Summary

How does Drugs Made In America Acquisition compare to UP Fintech?

Summary

How does Drugs Made In America Acquisition compare to Safehold?

Summary

How does Drugs Made In America Acquisition compare to Centerspace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools